(1Z)-1-[(2-hydroxyanilino)methylidene]naphthalen-2-one (HAMNO) [28], TDRL-505 [29], and fumaropimaric acid (NSC15520) [30,31] are well-characterized small molecule inhibitors targeting RPA70 in vitro, but their potential as cancer therapeutics requires further validation. This evidence concerns the gene RPA1 and cancer.